Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
November 01, 2023 03:00 ET
|
Cellectis Inc.
Collaboration leverages Cellectis’ gene editing technologies and manufacturing capabilities to develop up to 10 novel cell & gene therapy candidate productsCellectis to receive up to $245M in cash...
Cellectis présente des données précliniques sur des cellules « smart » MUC1- CAR T ciblant le cancer du sein triple négatif à l’occasion de la 38ème réunion annuelle de la Society for Immunotherapy of Cancer (SITC)
October 31, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, 31 oct. 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome...
Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
October 31, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress
October 24, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis présentera des données précliniques sur son programme de thérapie génique des HSPC ainsi qu’une analyse complète des TALE-BE lors du 30ème Congrès Annuel de l’ESGCT
October 24, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, 24 oct. 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome...
Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)
October 12, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis et l'Institut Imagine publient une étude de preuve de concept d'un candidat produit de chirurgie génique pour traiter le syndrome de la phosphoinositide 3-Kinase activée de type 1 (APDS1)
October 12, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, 12 oct. 2023 (GLOBE NEWSWIRE) -- Cellectis (la " Société ") (Euronext Growth : ALCLS - NASDAQ : CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière...
Monthly information on share capital and company voting rights
October 03, 2023 16:30 ET
|
Cellectis Inc.
PARIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
October 03, 2023 16:30 ET
|
Cellectis Inc.
PARIS, 03 oct. 2023 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth Code ISIN : FR0010425595DateNombre total d’actions composant le capital socialNombre total de droits de...
Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
September 27, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...